back to top
- Inherited Genetic Variants Increase the Likelihood of Developing Clonal Hematopoiesis: Something Akin to Pre-CHIPOctober 03, 2018 | November-December 2018, Volume 15, Issue 6
Dr. Keel discusses a study that helps further our understanding that inherited genetic variants increase the likelihood of developing clonal hematopoiesis.
- JAK1/2 Inhibitors Linked to Aggressive B-cell Lymphoma Risk in Myelofibrosis and Pre-existing B-cell Clones May Mark Those at RiskAugust 24, 2018 | September-October 2018, Volume 15, Issue 5
Dr. Keel looks at whether JAK1/2 inhibitor therapy in patients with myeloproliferative neoplasms alters the risk of lymphoma development.
- A Closer Look at Antiphospholipid Antibody Testing and Duration of Anticoagulation Decisions in Unprovoked Venous ThromboembolismJune 28, 2018 | July-August 2018, Volume 15, Issue 4
Dr. Keel discusses a study that addresses uncertainties about antiphospholipid antibody testing and duration of anticoagulation decisions in unprovoked venous thromboembolism.
- Germline Mutations in a Cohort of Inherited Marrow Failure Patients: A Varied LandscapeApril 12, 2018 | May-June 2018, Volume 15, Issue 3
Dr. Keel reviews work that expands our understanding of the inherited genetic underpinnings of marrow failure and hematologic malignancy predisposition.
- Can Iron Every (Other) Day Keep the Doctor Away?February 02, 2018 | March-April 2018, Volume 15, Issue 2
Dr. Keel looks at a study that recommends dosing of oral iron to be once every other day, rather than twice-daily, to overcome the hepcidin-mediated block of iron absorption.
- A Lot of Attention on Aplastic AnemiaJanuary 10, 2018 | January-February 2018, Volume 15, Issue 1
Dr. Keel looks at a study that reviews the use of eltrombopag in combination with antithymocyte globulin and cyclosporine in refractory severe aplastic anemia treatment-naive patients, among other studies.
- Improving Outcomes in High-Risk MDS and CMML: Which Needle(s) to Use Remain Lost in the HaystackOctober 10, 2017 | November-December 2017, Volume 14, Issue 6
Dr. Keel looks at a study that considers azacitidine-based combination chemotherapy as therapy for a subset of high-risk MDS patients with chronic myelomonocytic leukemia.
- Things Are Not Always What They Seem: Marrow Failure From a Hematopoietic Cell-Extrinsic Mechanism Due to Germline Mutations in ThrombopoietinAugust 14, 2017 | September-October 2017, Volume 14, Issue 5
Dr. Keel reviews a study that shows that patients with germline THPO mutations resulting in marrow failure do not benefit from stem cell transplantation, but instead respond to thrombopoietin mimetic therapy.
- Are We Recruiting an Army for Magneto? Optimizing Iron Utilization in HemodialysisJuly 01, 2017 | July-August 2017, Volume 14, Issue 4
Dr. Keel breaks down a study that looks at the use and effects of two different doses of intravenous iron in patients with chronic kidney disease on hemodialysis.
- Precision Medicine at Work: Genetic Profiling to Guide Stem-Cell Transplantation in Myelodysplastic SyndromesMay 01, 2017 | May-June 2017, Volume 14, Issue 3
Dr. Keel reviews the use of genetic profiling to guide stem-cell transplantation in myelodysplastic syndromes.
Dr. Keel is associate professor of medicine in the division of hematology at the University of Washington School of Medicine. Her clinical interests include benign red blood cell disorders, iron metabolism (including iron deficiency and hereditary hemochromatosis), acquired aplastic anemia, congenital marrow failure syndromes, and the transition of care between pediatric and adult hematologists. Her research interests include normal and ineffective erythropoiesis, systemic and cellular iron homeostasis, and the clinical presentation and molecular underpinnings of inherited marrow failure.
University of Washington School of Medicine